Evidence map›Paper›PMID 27528615›Full record

ArticleMolecular and cellular biology2016

Functional Differences of Very-Low-Density Lipoprotein Receptor Splice Variants in Regulating Wnt Signaling.

Qian Chen, Yusuke Takahashi, Kazuhiro Oka, Jian-Xing Ma

Open access · hybridAbstract read
In one paragraph

Article in Molecular and cellular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Soluble very low-density lipoprotein receptor (sVLDLR) inhibits fibrosis in neovascular age-related macular degeneration.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Wnt Signaling in vascular eye diseases.Progress in retinal and eye research · 2019
    Review
  10. The Reelin Receptors Apolipoprotein E receptor 2 (ApoER2) and VLDL Receptor.International journal of molecular sciences · 2018
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Qian ChenDepartment of Physiology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Harold Hamm Diabetes Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Yusuke TakahashiDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Harold Hamm Diabetes Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Kazuhiro OkaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Jian-Xing MaDepartment of Physiology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Harold Hamm Diabetes Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA jian-xing-ma@ouhsc.edu.
University of Oklahoma Health Sciences Center · USBaylor College of Medicine · US

Funding

Project 5 VEGF Signaling in PhotoreceptorsP20GM104934 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI LE, YUN ZHENG · 2012 to 2016
$10.8M
A new pathogenic mechanism for diabetic retinopathyR01EY019309 · NEI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Jian-Xing Jay Ma · 2009 to 2026
$6.1M
STUDIES OF RPE65R01EY012231 · NEI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MA, JIAN-XING, MOISEYEV, GENNADIY · 1998 to 2021
$5.7M
The wnt signaling pathway in choroidal neovascularizationR01EY018659 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MA, JIAN-XING · 2009 to 2019
$3.7M
NEI NIH HHS R01 EY012231NEI NIH HHS R01 EY018659NEI NIH HHS R01 EY019309NIGMS NIH HHS P20 GM104934
6 · The paper itself

Abstract

The very-low-density lipoprotein receptor (VLDLR) negatively regulates Wnt signaling. VLDLR has two major alternative splice variants, VLDLRI and VLDLRII, but their biological significance and distinction are unknown. Here we found that most tissues expressed both VLDLRI and VLDLRII, while the retina expressed only VLDLRII. The shed soluble VLDLR extracellular domain (sVLDLR-N) was detected in the conditioned medium of retinal pigment epithelial cells, interphotoreceptor matrix, and mouse plasma, indicating that ectodomain shedding of VLDLR occurs endogenously. VLDLRII displayed a higher ectodomain shedding rate and a more potent inhibitory effect on Wnt signaling than VLDLRI in vitro and in vivo O-glycosylation, which is present in VLDLRI but not VLDLRII, determined the differential ectodomain shedding rates. Moreover, the release of sVLDLR-N was inhibited by a metalloproteinase inhibitor, TAPI-1, while it was promoted by phorbol 12-myristate 13-acetate (PMA). In addition, sVLDLR-N shedding was suppressed under hypoxia. Further, plasma levels of sVLDLR-N were reduced in both type 1 and type 2 diabetic mouse models. We concluded that VLDLRI and VLDLRII had differential roles in regulating Wnt signaling and that decreased plasma levels of sVLDLR-N may contribute to Wnt signaling activation in diabetic complications. Our study reveals a novel mechanism for intercellular regulation of Wnt signaling through VLDLR ectodomain shedding.

Indexed as

Wnt Signaling PathwayAnimalsCells, CulturedCulture Media, ConditionedDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Disease Models, AnimalDown-RegulationGlycosylationHumansMiceProtein IsoformsReceptors, LDLRetinaRetinal Pigment EpitheliumTissue DistributionCulture Media, ConditionedProtein IsoformsReceptors, LDLVLDL receptor

Identifiers

PMID27528615
PMCPMC5038150
OpenAlexW2524882762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.